Atomera Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Atomera Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $62.0K | Feb 19, 2021 |
| FY2020 | Dec 31, 2019 | $533.0K | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $246.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $110.0K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 6, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $135.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $550.0K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $382.0K | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $400.0K | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $62.0K | Feb 15, 2022 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($256.0K) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $12.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $522.0K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $301.0K | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $400.0K | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $49.0K | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $280.0K | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $98.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $71.0K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $0 | Mar 6, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.17M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($18.44M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($19.79M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($17.44M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($15.71M) | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | ($14.88M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | ($13.30M) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($12.90M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($13.07M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($12.61M) | Mar 6, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($21.12M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($19.34M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($20.68M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($17.53M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($15.53M) | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | ($14.92M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | ($13.63M) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($13.13M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($13.21M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($10.00M) | Mar 6, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.30M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $11.03M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $12.53M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $10.04M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $8.78M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $8.42M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $7.75M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $7.32M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $5.83M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $3.99M | Mar 6, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.87M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($13.24M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($14.56M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($12.50M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($12.44M) | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | ($12.07M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | ($10.41M) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($9.77M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($9.29M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($6.80M) | Mar 6, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.0K | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $14.0K | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $31.0K | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $39.0K | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $109.0K | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $131.0K | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $51.0K | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $23.0K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $60.0K | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $28.0K | Mar 6, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.09M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $29.12M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $24.03M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $26.73M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $36.06M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $39.40M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $15.24M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $19.36M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $17.81M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | $26.88M | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.71M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $4.05M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $5.86M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $6.42M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $7.68M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $2.05M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | $1.47M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.61M | Mar 13, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.38M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $25.08M | Feb 24, 2026 |
| FY2025 | Dec 31, 2023 | $18.17M | Feb 24, 2026 |
| FY2024 | Dec 31, 2022 | $20.31M | Mar 4, 2025 |
| FY2023 | Dec 31, 2021 | $28.38M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $37.35M | Feb 15, 2023 |
| FY2021 | Dec 31, 2019 | $13.77M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $17.75M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $16.86M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $25.85M | Mar 11, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($241.69M) | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | ($221.52M) | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | ($203.09M) | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | ($183.30M) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($165.85M) | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | ($150.14M) | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | ($135.26M) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($121.96M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($109.07M) | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | ($96.00M) | Mar 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.21M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | $25.78M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | $12.59M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | $21.18M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $28.70M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | $37.94M | Feb 15, 2022 |
| FY2021 | Dec 31, 2019 | $14.87M | Feb 15, 2022 |
| FY2020 | Dec 31, 2018 | $18.93M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $17.37M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $26.72M | Mar 11, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 15, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 15, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 32.35M | Feb 24, 2026 |
| FY2025 | Dec 31, 2024 | 30.54M | Feb 24, 2026 |
| FY2024 | Dec 31, 2023 | 26.11M | Mar 4, 2025 |
| FY2023 | Dec 31, 2022 | 23.97M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 23.21M | Feb 15, 2023 |
| FY2021 | Dec 31, 2020 | 22.38M | Feb 15, 2022 |
| FY2020 | Dec 31, 2019 | 17.12M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 15.03M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 12.16M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | 12.03M | Mar 6, 2018 |